---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-012083"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T00:34:53.054111+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Roivant Sciences appoints Meghan FitzGerald to board and Ilan Oren as Chairman

## Summary
- Meghan M. FitzGerald appointed as Class II director and member of Nominating & Governance Committee, effective March 13, 2023.
- FitzGerald is a global healthcare strategist with experience at Cardinal Health, Pfizer, Sanofi, and adjunct professor at Columbia University.
- Board appointed Ilan Oren as Chairman; Oren has been a director since 2014 and Co-CEO of Dexcel Pharma.
- FitzGerald will receive cash and equity compensation per company's Non-Executive Director Compensation Policy; initial equity grant in April 2023.

## SEC filing metadata
- accession: 0001140361-23-012083
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036123012083/0001140361-23-012083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036123012083/brhc10049884_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-012083
- JSON: https://secwatch.observer/filing/0001140361-23-012083.json
- Plain text: https://secwatch.observer/filing/0001140361-23-012083.txt

## Key facts
- Executive change
  Ilan Oren was appointed as Chairman of the Board at Roivant Sciences Ltd..
  - Action: appointed
  - Role: Chairman of the Board
  source text: In addition, the Board has appointed Ilan Oren as Chairman of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1635088/000114036123012083/0001140361-23-012083-index.htm
- Executive change
  Meghan M. FitzGerald was appointed as Class II Director at Roivant Sciences Ltd..
  - Action: appointed
  - Role: Class II Director
  source text: On March 13, 2023, the Board of Directors (the “Board”) of Roivant Sciences Ltd. (the “Company”) appointed Meghan M. FitzGerald, DrPH, to serve as a Class II director of the Company and as a member of the Nominating and Governance Committee of the Board, effective as of that date, filling a vacancy on the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1635088/000114036123012083/0001140361-23-012083-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.